ArticleNature2020
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 480 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
480citing papers in PubMed, 1 pooled it
13.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
480 citing papers in PubMed, 1 synthesis or guideline pooled it, 676 citations in OpenAlex.
- Tracing the origin of Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A systematic review and narrative synthesis.Journal of medical virology · 2022Pooled it
- Early Treatment with Pegylated Interferon Lambda for Covid-19.The New England journal of medicine · 2023Trial
- The CCR2 inflammatory pathway is a target for improving severe disease and pulmonary inflammation in experimental COVID-19.Virulence · 2026Article
- Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells.Science advances · 2026Article
- SARS-CoV-2 infection produces an IL-33-dependent chronic eosinophilic pneumonia and muco-inflammatory airways disease in Scnn1b-Tg mice.JCI insight · 2026Article
- Development and characterization of mouse-adapted recombinant SARS-CoV-2 expressing reporter genes.Microbiology spectrum · 2026Article
- Triple IFN pathway deficiency sensitizes mice to human respiratory virus infection independent of human viral receptor expression.Nature communications · 2026Article
- The Role of Human Viral Entry Receptor Mouse Models in Advancing Antiviral Antibodies and Vaccines.Vaccines · 2026Review
- Clade-3 Bat Sarbecovirus PRD0038 Reveals Constraints on Coronavirus Emergence and Immune Sensitivity.Research square · 2026Article
- Humanized immune system animal models and their recent applications.Animal models and experimental medicine · 2026Review
- Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells.bioRxiv : the preprint server for biology · 2026Article
- Differential effects of SARS-CoV-2-targeted infection of ATII, club cells, and macrophages on lung immunopathology and antiviral responses.Mucosal immunology · 2026Article
- Exosomal ORF3a mediates lung-liver axis to dysregulate hepatic lipid metabolism in mild COVID-19.Cell discovery · 2026Article
- SARS-CoV-2 infection is associated with hypothalamic orexin suppression and persistent cortical NeuN attenuation.Journal of neuroinflammation · 2026Article
- The hyaluronan receptor CD44 drives COVID-19 severity through its regulation of neutrophil migration.PLoS pathogens · 2026Article
- In vivo Assessment of the Potential Protective Effects of Traditional Kumis Against SARS-CoV-2 in a Transgenic Mouse Model.Food and environmental virology · 2026Article
- CGM23 corresponds to a pan-coronavirus lipopeptide inhibitor potently inhibiting virion fusion.iScience · 2026Article
- Infection of 5xFAD mice with a mouse-adapted SARS-CoV-2 does not alter Alzheimer's disease neuropathology yet induces widespread changes in gene expression across diverse cell types.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- CD4 T-cell platform for delivering interferons as an antiviral countermeasure with a focus on SARS-CoV-2.Molecular medicine (Cambridge, Mass.) · 2026Article
- Lung Dysfunction and Systemic Inflammation: A Role for HO-1 and NLRP3 in a COVID-19 Murine Model.Research square · 2026Article
420 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Update of
Authors and funding
19 authors at 3 institutions in 1 country.
Kenneth H Dinnon *Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-8942-1551
Sarah R Leist *Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Caitlin E EdwardsDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0003-4228-2192
David R MartinezDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Stephanie A MontgomeryDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-8012-5302
Ande WestDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Boyd L YountDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Yixuan J HouDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-8323-7243
Lily E AdamsDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-7780-9973
Kendra L GullyDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ariane J BrownDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Emily HuangDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Matthew D BryantEiger BioPharmaceuticals, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0001-9143-9403
Ingrid C ChoongEiger BioPharmaceuticals, Palo Alto, CA, USA.
Jeffrey S GlennDepartments of Medicine and Microbiology and Immunology, Stanford University, Stanford, CA, USA.
Lisa E GralinskiDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Timothy P SheahanDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-9181-2183
Ralph S BaricDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. rbaric@email.unc.edu.ORCID http://orcid.org/0000-0001-6827-8701
University of North Carolina at Chapel Hill · USEiger Biopharmaceuticals (United States) · USPalo Alto Veterans Institute for Research · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MProject 4 - Influenza - UABU19AI142759 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WHITLEY, RICHARD J. · 2019 to 2023
$37.5MUnlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MCWEENEY, SHANNON K. · 2012 to 2021
$36.6MVector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Martina Gentzsch · 2004 to 2026
$26.5MBroad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoVR01AI132178 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, SHEAHAN, TIMOTHY PATRICK · 2017 to 2021
$7.0MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MINFECTIOUS DISEASE PATHOGENESIS TRAININGT32AI007151 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 1985 to 2024
$5.5MMolecular Biology of Viral Diseases Predoctoral Training GrantT32AI007419 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark T Heise, CARY A MOODY · 1993 to 2026
$4.7MNCI NIH HHS P30 CA016086NIAID NIH HHS R01 AI132178NIAID NIH HHS R01 AI157155NIAID NIH HHS T32 AI007151NIAID NIH HHS T32 AI007419NIAID NIH HHS U19 AI100625NIAID NIH HHS U19 AI142759NIDDK NIH HHS P30 DK065988NIH HHS 1U19AI142759NIH HHS 5P30CA016086-41NIH HHS 5R01AI132178NIH HHS DK065988
Abstract
Coronaviruses are prone to transmission to new host species, as recently demonstrated by the spread to humans of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic
Indexed as
BetacoronavirusDisease Models, AnimalAgingAngiotensin-Converting Enzyme 2AnimalsCoronavirus InfectionsCOVID-19COVID-19 VaccinesFemaleForkhead Transcription FactorsHumansInterferon-alphaInterferon LambdaInterferonsInterleukinsMaleACE2 protein, humanAce2 protein, mouseAngiotensin-Converting Enzyme 2COVID-19 VaccinesForkhead Transcription FactorsFOXJ1 protein, mouseInterferon-alphaInterferon Lambdainterferon-lambda, humanInterferonsInterleukinsPeptidyl-Dipeptidase AReceptors, VirusViral Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.